Product Details
Retatrutide
Basic Info.
Retatrutide is an experimental drug developed by Eli Lilly and Company in the United States for the treatment of obesity. It is a triple glucagon hormone receptor agonist.
In a phase II clinical trial, the drug has been proved to reduce the average weight of non diabetes but obese or pre obese (overweight) adults by more than 17.5%
Areas of Expertise
-
Leading-Edge Manufacturing Capabilityg
-
Advanced R&D and State-of-the-Art Facilities
-
Versatile and Scalable Packaging Solutions
-
Certified Quality & International Compliance
English